NO20040803L - Anvendelse av atazanavir i HIV terapi - Google Patents

Anvendelse av atazanavir i HIV terapi

Info

Publication number: NO20040803L
Authority: NO; Norway
Prior art keywords: atazanavir; hiv; protease inhibitor; triglyceride levels; hiv therapy
Prior art date: 2001-08-31

Application number

NO20040803A

Other languages

English (en)

Norwegian (no)

Inventor

Clifford M Bechtold

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-31

Filing date

2004-02-24

Publication date

2004-02-24

2004-02-24 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2004-02-24 Publication of NO20040803L publication Critical patent/NO20040803L/no

Links

AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 title abstract 3
108010019625 Atazanavir Sulfate Proteins 0.000 title abstract 3
229960003277 atazanavir Drugs 0.000 title abstract 3
AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 title abstract 3
238000002560 therapeutic procedure Methods 0.000 title abstract 2
229940122440 HIV protease inhibitor Drugs 0.000 abstract 2
239000004030 hiv protease inhibitor Substances 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 2
102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 abstract 1
208000031886 HIV Infections Diseases 0.000 abstract 1
208000037357 HIV infectious disease Diseases 0.000 abstract 1
108010028554 LDL Cholesterol Proteins 0.000 abstract 1
238000008214 LDL Cholesterol Methods 0.000 abstract 1
108010007622 LDL Lipoproteins Proteins 0.000 abstract 1
101710198130 NADPH-cytochrome P450 reductase Proteins 0.000 abstract 1
230000001747 exhibiting effect Effects 0.000 abstract 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Tropical Medicine & Parasitology (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

NO20040803A 2001-08-31 2004-02-24 Anvendelse av atazanavir i HIV terapi NO20040803L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US31674501P	2001-08-31	2001-08-31
PCT/US2002/026675 WO2003020206A2 (en)	2001-08-31	2002-08-21	Use of atazanavir in hiv therapy

Publications (1)

Publication Number	Publication Date
NO20040803L true NO20040803L (no)	2004-02-24

Family

ID=23230468

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20040803A NO20040803L (no)	2001-08-31	2004-02-24	Anvendelse av atazanavir i HIV terapi

Country Status (27)

Country	Link
US (1)	US20030045501A1 (de)
EP (1)	EP1420799B1 (de)
JP (1)	JP2005501880A (de)
KR (1)	KR20040029447A (de)
CN (1)	CN1245988C (de)
AT (1)	ATE341332T1 (de)
AU (1)	AU2002332610B2 (de)
BG (1)	BG108585A (de)
BR (1)	BR0211544A (de)
CA (1)	CA2458807A1 (de)
CZ (1)	CZ2004288A3 (de)
DE (1)	DE60215189T2 (de)
DK (1)	DK1420799T3 (de)
EE (1)	EE200400065A (de)
ES (1)	ES2274119T3 (de)
HR (1)	HRP20040181A2 (de)
HU (1)	HUP0401091A2 (de)
IL (1)	IL159849A0 (de)
IS (1)	IS7158A (de)
MX (1)	MXPA04001721A (de)
NO (1)	NO20040803L (de)
NZ (1)	NZ530722A (de)
PL (1)	PL367873A1 (de)
RU (1)	RU2316341C2 (de)
WO (1)	WO2003020206A2 (de)
YU (1)	YU12204A (de)
ZA (1)	ZA200401412B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7390504B2 (en) *	2003-11-07	2008-06-24	Jj Pharma, Inc.	HDL-boosting combination therapy complexes
US20050148523A1 (en) *	2003-12-15	2005-07-07	Colonno Richard J.	Method of treating HIV infection in atazanavir-resistant patients using a combination of atazanavir and another protease inhibitor
KR20120029480A (ko)	2007-06-12	2012-03-26	콘서트 파마슈티컬즈, 인크.	아자펩티드 유도체
SI2170292T1 (sl) *	2007-06-22	2014-05-30	Bristol-Myers Squibb Holdings Ireland	Tabletirani sestavki, ki vsebujejo atazanavir
JP2010530889A (ja) *	2007-06-22	2010-09-16	ブリストル−マイヤーズスクイブカンパニー	アタザナビルを含む錠剤組成物
JP2010530892A (ja) *	2007-06-22	2010-09-16	ブリストル−マイヤーズスクイブカンパニー	アタザナビルを含む錠剤組成物
ES2359770T3 (es) *	2007-06-22	2011-05-26	Bristol-Myers Squibb Company	Composiciones en comprimidos que contienen atazanavir.
EP2214668A1 (de) *	2007-10-29	2010-08-11	Cipla Limited	Neue antiretrovirale kombination
CN101249138B (zh) *	2008-03-28	2012-03-21	中国人民解放军军事医学科学院野战输血研究所	一种含五味子乙醇提取物的抗艾滋病药物组合物
MX2012011415A (es) *	2010-04-02	2013-02-26	Phivco 1 Llc	Terapia de combinacion que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinetico.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2188638C2 (ru) *	1996-04-04	2002-09-10	Шионоги Энд Ко., Лтд.	Анти-вич-композиция, содержащая имидазольные производные

2002
- 2002-08-21 KR KR10-2004-7002851A patent/KR20040029447A/ko not_active Ceased
- 2002-08-21 EP EP02797744A patent/EP1420799B1/de not_active Expired - Lifetime
- 2002-08-21 HR HR20040181A patent/HRP20040181A2/xx not_active Application Discontinuation
- 2002-08-21 PL PL02367873A patent/PL367873A1/xx not_active Application Discontinuation
- 2002-08-21 AT AT02797744T patent/ATE341332T1/de not_active IP Right Cessation
- 2002-08-21 WO PCT/US2002/026675 patent/WO2003020206A2/en not_active Ceased
- 2002-08-21 DE DE60215189T patent/DE60215189T2/de not_active Expired - Fee Related
- 2002-08-21 DK DK02797744T patent/DK1420799T3/da active
- 2002-08-21 ES ES02797744T patent/ES2274119T3/es not_active Expired - Lifetime
- 2002-08-21 US US10/225,754 patent/US20030045501A1/en not_active Abandoned
- 2002-08-21 RU RU2004106787/14A patent/RU2316341C2/ru not_active IP Right Cessation
- 2002-08-21 CZ CZ2004288A patent/CZ2004288A3/cs unknown
- 2002-08-21 IL IL15984902A patent/IL159849A0/xx unknown
- 2002-08-21 BR BR0211544-1A patent/BR0211544A/pt not_active IP Right Cessation
- 2002-08-21 AU AU2002332610A patent/AU2002332610B2/en not_active Ceased
- 2002-08-21 CN CNB028166868A patent/CN1245988C/zh not_active Expired - Fee Related
- 2002-08-21 MX MXPA04001721A patent/MXPA04001721A/es active IP Right Grant
- 2002-08-21 CA CA002458807A patent/CA2458807A1/en not_active Abandoned
- 2002-08-21 JP JP2003524520A patent/JP2005501880A/ja not_active Withdrawn
- 2002-08-21 HU HU0401091A patent/HUP0401091A2/hu unknown
- 2002-08-21 NZ NZ530722A patent/NZ530722A/en unknown
- 2002-08-21 EE EEP200400065A patent/EE200400065A/xx unknown
- 2002-08-21 YU YU12204A patent/YU12204A/sh unknown
2004
- 2004-02-17 BG BG108585A patent/BG108585A/bg unknown
- 2004-02-19 IS IS7158A patent/IS7158A/is unknown
- 2004-02-20 ZA ZA200401412A patent/ZA200401412B/en unknown
- 2004-02-24 NO NO20040803A patent/NO20040803L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
RU2316341C2 (ru)	2008-02-10
CN1547476A (zh)	2004-11-17
DE60215189T2 (de)	2007-10-25
IS7158A (is)	2004-02-19
WO2003020206A3 (en)	2003-10-02
PL367873A1 (en)	2005-03-07
CN1245988C (zh)	2006-03-22
US20030045501A1 (en)	2003-03-06
ZA200401412B (en)	2005-03-18
BG108585A (bg)	2005-04-30
NZ530722A (en)	2007-11-30
HK1061640A1 (en)	2004-09-30
DK1420799T3 (da)	2007-01-15
EE200400065A (et)	2004-06-15
JP2005501880A (ja)	2005-01-20
EP1420799B1 (de)	2006-10-04
WO2003020206A2 (en)	2003-03-13
DE60215189D1 (de)	2006-11-16
CZ2004288A3 (cs)	2004-12-15
YU12204A (sh)	2006-08-17
AU2002332610B2 (en)	2007-11-08
CA2458807A1 (en)	2003-03-13
EP1420799A2 (de)	2004-05-26
BR0211544A (pt)	2004-07-13
HRP20040181A2 (en)	2004-08-31
ES2274119T3 (es)	2007-05-16
EP1420799A4 (de)	2004-11-24
HUP0401091A2 (hu)	2004-08-30
ATE341332T1 (de)	2006-10-15
IL159849A0 (en)	2004-06-20
MXPA04001721A (es)	2004-05-31
KR20040029447A (ko)	2004-04-06

Legal Events

Date	Code	Title	Description
2009-03-30	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
EP4445900A3 (de)	2024-10-23	Therapeutische verbindungen gegen hiv-virus-infektion
DK1420799T3 (da)	2007-01-15	Anvendelse af atazanavir i HIV-behandling
TW200510397A (en)	2005-03-16	Conjugated complement cascade inhibitors
SI1677827T1 (sl)	2009-06-30	Zdravilni sestavek proti virusu hepatitisa c (hcv)
DK1293207T3 (da)	2009-10-05	Anvendelse af ritonavir (ABT-538) til forbedring af farmokokinetikken af lægemidler, som metaboliseres af cytochrome P450 i en fremgangsmåde til at behandle AIDS
ATE534433T1 (de)	2011-12-15	Kombinierte verwendung von enzyminhibitoren zur therapie und prävention allergischer reaktionen vom typ i nach gell und coombs und zur therapie und prävention dermatologischer erkrankungen mit follikulären und epidermalen hyperkeratosen und einer verstärkten keratinozytenproliferation
ECSP034922A (es)	2004-04-28	Pirrolopirimidinas
AU2002236795A1 (en)	2002-08-12	Compositions and method of tissue superoxygenation
AU2002302587A1 (en)	2002-11-18	Acne treatment with lipooxigenase inhibitors
NO944997L (no)	1994-12-23	Trombin-blodfraksjon for anvendelse ved en medisinsk fremgangsmåte
WO2003024386A8 (en)	2004-06-24	Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
NO20034094D0 (no)	2003-09-15	Sammensetninger som omfatter et antidiar±middel og et epotilon eller et epotilonderivat
EA200702242A1 (ru)	2008-02-28	Использование сульфонамидного соединения для улучшения фармакокинетики лекарственного средства
CA2469343A1 (en)	2003-06-19	Combination of cytochome p450 dependent protease inhibitors
WO2003004006A3 (en)	2003-05-30	Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
HRP20050557A2 (en)	2006-05-31	Method for improving the pharmacokinetics of a nnrti
RU2004106787A (ru)	2004-12-10	Применение атазанавира в терапии вич-инфекции
MX2022008532A (es)	2022-09-09	Inhibidores de hidrocarburo de arilo (ahr) y usos de estos.
DK1441708T3 (da)	2009-07-06	Sammensætninger og fremgangsmåder til forögelse af föjelighed med terapier ved anvendelse af aldehyddehydrogenase-inhibitorer og behandling af alkoholisme
EP1696918A4 (de)	2008-12-31	Verfahren zur behandlung von hiv-infektionen bei patienten mit atazanavir-resistenz unter verwendung einer kombination von atazanavir und einem anderen proteasehemmer
AU2002317877A1 (en)	2003-02-17	Use of a lactate salt for the treatment and prophylaxis of atherosclerosis
WO2021262437A3 (en)	2022-02-10	Use of il13 for prevention and treatment of covid-19
WO2023069461A3 (en)	2023-06-01	Method for the prevention and treatment of coronavirus disease
UA28400A (uk)	2000-10-16	Спосіб лікування мікробної екземи
UA3215U (uk)	2004-10-15	Спосіб лікування пацієнтів хворих фосааксиляріозом